Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial

Top Cited Papers
Open Access
Publisher Website
Google Scholar
Abstract
Tamoxifen, a selective estrogen receptor modulator (SERM)1 that has been used to treat both early and advanced breast cancer for more than 3 decades,2 has been thoroughly evaluated for the reduction of the risk of both invasive and noninvasive breast cancer in women at increased risk.3-9 Raloxifene, a second-generation SERM,1 has been shown to reduce the incidence of mammary malignancy in preclinical models,10-12 and several clinical trials evaluating it for the prevention and treatment of osteoporosis have suggested that it may also have a role in reducing the risk of invasive breast cancer in postmenopausal women.13-20